Paul Bhar

4.8k total citations · 2 hit papers
34 papers, 3.6k citations indexed

About

Paul Bhar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Paul Bhar has authored 34 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Paul Bhar's work include Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (7 papers). Paul Bhar is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (9 papers) and Breast Cancer Treatment Studies (7 papers). Paul Bhar collaborates with scholars based in United States, Russia and Switzerland. Paul Bhar's co-authors include Michael Hawkins, William J. Gradishar, Neil Desai, Joyce O’Shaughnessy, Sergei Tjulandin, Neville Davidson, Heather Shaw, Anatoly Makhson, С. В. Орлов and George Manikhas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Paul Bhar

33 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

2005 1.6k citations William J. Gradishar, Sergei Tjulandin et al. Journal of Clinical Oncology profile →
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Mark A. Socinski, Anatoly Makhson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Bhar United States	15	2.1k	1.0k	835	709	647	34	3.6k
Neville Davidson United Kingdom	14	3.7k 1.7×	596 0.6×	1.2k 1.4×	1.3k 1.8×	398 0.6×	25	5.0k
Vuong Trieu United States	23	2.0k 0.9×	969 0.9×	581 0.7×	1.2k 1.7×	565 0.9×	92	4.1k
Hilary Calvert United Kingdom	31	2.6k 1.2×	394 0.4×	1.5k 1.8×	2.2k 3.1×	319 0.5×	79	5.0k
Barbara Haley United States	21	1.7k 0.8×	404 0.4×	629 0.8×	759 1.1×	431 0.7×	56	2.9k
Noe Kyeong Kim South Korea	24	1.7k 0.8×	468 0.4×	1.4k 1.7×	988 1.4×	271 0.4×	60	3.4k
Lowell L. Hart United States	37	3.5k 1.6×	330 0.3×	2.2k 2.7×	1.7k 2.4×	293 0.5×	127	5.5k
George P. Stathopoulos Greece	28	1.4k 0.6×	391 0.4×	457 0.5×	689 1.0×	230 0.4×	105	2.6k
Anatoly Makhson Russia	7	4.2k 2.0×	393 0.4×	1.9k 2.3×	810 1.1×	278 0.4×	11	5.3k
Lucia Viganò Italy	23	1.4k 0.7×	248 0.2×	296 0.4×	1.3k 1.9×	249 0.4×	38	2.9k
Holly E. Barker United Kingdom	16	1.7k 0.8×	190 0.2×	789 0.9×	1.8k 2.6×	619 1.0×	27	3.9k

Countries citing papers authored by Paul Bhar

Since Specialization

Citations

This map shows the geographic impact of Paul Bhar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Bhar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Bhar more than expected).

Fields of papers citing papers by Paul Bhar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Bhar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Bhar. The network helps show where Paul Bhar may publish in the future.

Co-authorship network of co-authors of Paul Bhar

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Bhar. A scholar is included among the top collaborators of Paul Bhar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Bhar. Paul Bhar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khagi, Simon, Jose Carrillo, David Park, et al.. (2025). CTIM-23. FIRST-IN-HUMAN IMMUNOTHERAPY TARGETING LYMPHOPENIA IN RECURRENT GLIOBLASTOMA MULTIFORM (GBM): NAI AND PD-L1 T-HANK PLUS BEVACIZUMAB WITH COMPLETE RESPONSE. Neuro-Oncology. 27(Supplement_5). v119–v119.

Seery, Tara Elisabeth, Chaitali Nangia, Paul Bhar, et al.. (2022). Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.. Journal of Clinical Oncology. 40(16_suppl). 4147–4147. 3 indexed citations

Chamie, Karim, Sam S. Chang, Mark L. Gonzalgo, et al.. (2022). Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 40(16_suppl). 4508–4508. 38 indexed citations

Chamie, Karim, Sam S. Chang, Mark L. Gonzalgo, et al.. (2021). Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.. Journal of Clinical Oncology. 39(6_suppl). 510–510. 17 indexed citations

Chamie, Karim, Sam S. Chang, Mark L. Gonzalgo, et al.. (2021). PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS.. The Journal of Urology. 206(Supplement 3). 1 indexed citations

Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2012). Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer. 12(5). 313–321. 91 indexed citations

O’Shaughnessy, Joyce, et al.. (2012). Abstract P1-12-07: A Retrospective Analysis of nab-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients With Poor Prognostic Factors. Cancer Research. 72(24_Supplement). P1–12. 2 indexed citations

Aapro, Matti, Sergei Tjulandin, Paul Bhar, & William J. Gradishar. (2011). Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis. The Breast. 20(5). 468–474. 33 indexed citations

Gradishar, WJ, et al.. (2011). P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.. Cancer Research. 71(24_Supplement). P5–19. 1 indexed citations

10.

Biakhov, M., José Iglesias, Neil Desai, et al.. (2010). nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opinion on Drug Safety. 9(4). 515–523. 14 indexed citations

11.

Socinski, Mark A., G. Manikhas, А. Н. Махсон, et al.. (2010). A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 852–861. 67 indexed citations

12.

Pippen, John, J. O’Shaughnessy, Christopher Stokoe, et al.. (2009). 0151 Adjuvant dose-dense adriamycin plus cytoxan followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: A pilot study. The Breast. 18. S57–S57. 1 indexed citations

13.

Aapro, Matti, S. Tjulandin, Paul Bhar, & WJ Gradishar. (2008). Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer. European Journal of Cancer Supplements. 6(7). 177–177. 1 indexed citations

14.

Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2008). Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 6(7). 172–172. 6 indexed citations

15.

Vukelja, Svetislava J., Joyce O’Shaughnessy, D. Krasnojon, et al.. (2008). Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1082–1082. 1 indexed citations

16.

Hawkins, Michael, G. Manikhas, А. Н. Махсон, et al.. (2007). Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7659–7659. 5 indexed citations

17.

Manikhas, George, С. В. Орлов, Boris V. Afanasyev, et al.. (2006). Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology. 17(8). 1263–1268. 499 indexed citations

18.

Hawkins, Michael, et al.. (2006). Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 7132–7132. 7 indexed citations

19.

Gradishar, William J., Sergei Tjulandin, Neville Davidson, et al.. (2005). Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer. Journal of Clinical Oncology. 23(31). 7794–7803. 1571 indexed citations breakdown →

20.

Ibrahim, Nuhad K., Brian L. Samuels, Ray D. Page, et al.. (2005). Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer. Journal of Clinical Oncology. 23(25). 6019–6026. 205 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact